

Financial Tear Sheet

Primary IR Contact

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com
(mailto:invest@ctibiopharma.com)

Transfer Agent

Computershare

Mail:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078

Overnight Delivery:
Computershare Investor Services
250 Royall Street
Canton, MA 02021
United States of America

T: 312-588-4187
F: 312-601-4332
www.Computershare.com
(http://www.computershare.com)

Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$3.84**

Change (%) ▼ 0.04 (1.03%)

Volume 17,851

52 Week Low \$2.45

Market Cap \$224,966,707

Rolling EPS -1.29

PE Ratio 0

Shares Outstanding 57,981,110

Data as of 04/20/18 12:20 p.m. ET



Recent Headlines & Events

Mar 09, 2018 - 7:05 a.m.

CTI BioPharma to Present at Upcoming Investor Conferences

(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2337284)

Mar 09, 2018 - 7:00 a.m.

CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology

(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2337281)

Mar 07, 2018 - 4:01 p.m.

CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results

(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2336850)

There are currently no events scheduled.

Ownership Summary

Shareholders

| | Holders | Value (\$MM) | % O/S | Shares |
|-------------|----------------|---------------------|--------------|---------------|
| Institution | 80 | 90.58 | 45.5 | 26,393,289 |
| Mutual Fund | 30 | 21.91 | 9.5 | 5,520,559 |
| Insider * | 7 | 2.77 | 1.2 | 691,405 |

**Insider values reflect direct beneficial ownership.*

Top Holders

| | Shares Held | % O/S | Share Change | Filing Date |
|---|--------------------|--------------|---------------------|--------------------|
| BVF Partners L.P. | 6,929,690 | 12.0 | -1,666,667 | 02/09/18 |
| OrbiMed Advisors, LLC | 5,000,000 | 8.6 | 0 | 12/31/17 |
| New Enterprise Associates (NEA) | 3,750,000 | 6.5 | 3,750,000 | 02/08/18 |
| Stonepine Capital Management, LLC | 2,150,000 | 3.7 | 315,162 | 01/11/18 |
| Franklin Advisers, Inc. | 2,133,300 | 3.7 | 2,133,300 | 03/31/18 |
| NB Public Equity Komplementar ApS | 1,356,635 | 2.3 | 90,000 | 12/31/16 |
| The Vanguard Group, Inc. | 850,881 | 1.5 | -225,168 | 12/31/17 |
| Sphera Funds Management Ltd. | 833,633 | 1.4 | 0 | 12/31/17 |
| Renaissance Technologies LLC | 609,849 | 1.1 | 198,700 | 12/31/17 |
| BlackRock Institutional Trust Company, N.A. | 406,748 | 0.7 | 7,586 | 12/31/17 |

Data provided by Nasdaq. Minimum 15 minutes delayed.